News
Missouri Technology Corporation awards BIOIO a second MTC IDEA FUND in the January 2026 funding cycle.
BIOIO closes its seed round. Amongst the seed syndicate are notable longevity investors Lifespan Vision Ventures and quadraScope and regional investors Missouri Technology Corporation and BioGenerator Ventures.
BIOIO adds Ildiko Lingvay, MD, a pioneering clinical trialist for the GLP-1 RAs and Professor at Univ. of Texas Southwestern to its Scientific Advisory Board.
Missouri Technology Corporation, a for-profit public private partnership awarded BIOIO seed funding in its January 2024 investment cycle.
BIOIO-2001 was funded by VitaDAO using Molecule’s IP-NFT framework.

